Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial
Finnian R. Mc Causland, Brian Claggett, Marc A. Pfeffer, Emmanuel A. Burdmann, Kai‐Uwe Eckardt, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Patrick S. Parfrey (2017). Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. , 46(6), DOI: https://doi.org/10.1159/000485326.
